In:
Cancer Research, American Association for Cancer Research (AACR), Vol. 71, No. 8_Supplement ( 2011-04-15), p. 1568-1568
Abstract:
Circulating microvesicles (cMV) are membrane-bound structures that play an important role in several biologic processes, including angiogenesis and immune modulation. cMV levels are known to change in response to certain pathologies, and specific subpopulations of cMV can be isolated using antibodies targeted to membrane proteins specific for the secreting cells. We examined whether the levels of specific cMV subpopulations are altered in patients with a disease, specifically breast cancer. In order to characterize individual cancer-associated microvesicles (MVs), advanced breast cancer MVs were compared with normal control MVs. Circulating microvesicles were isolated from breast cancer patients or noncancer control patients, stained with fluorochrome-conjugated antibodies, and analyzed using flow cytometry. Tumor-specific antibodies were paired with process-specific markers, such as DLL4 and VEGFR2 for angiogenic cMV, CTLA4 and FasL for immunosuppressive cMV, and CD80 or CD83 for immunostimulatory cMV, to identify and characterize cMV subpopulations. Using this approach, distinct and informative cMV subpopulations were identified and quantified between breast cancer patients and healthy controls. For example, immunosuppressive MVs were elevated in the cancer patients compared with noncancer controls (68% vs 44% of CD45+ cMV coexpressed CTLA4). Additionally, angiogenic MVs were elevated in cancer plasma, with 44% coexpressing DLL4 and CD31 compared with 2% of cMV from noncancer controls. This study suggests that in addition to aiding diagnosis, monitoring specific subpopulations of cMV may offer important information regarding biologic processes perturbed by breast cancer in an individual patient, without the need for an invasive biopsy or a standard pathology evaluation such as immunohistochemistry, and therefore may also aid in prognosis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1568. doi:10.1158/1538-7445.AM2011-1568
Type of Medium:
Online Resource
ISSN:
0008-5472
,
1538-7445
DOI:
10.1158/1538-7445.AM2011-1568
Language:
English
Publisher:
American Association for Cancer Research (AACR)
Publication Date:
2011
detail.hit.zdb_id:
2036785-5
detail.hit.zdb_id:
1432-1
detail.hit.zdb_id:
410466-3
Permalink